A detailed history of Pro Share Advisors LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 16,244 shares of IMVT stock, worth $446,872. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,244
Previous 19,877 18.28%
Holding current value
$446,872
Previous $642,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$25.1 - $31.61 $91,188 - $114,839
-3,633 Reduced 18.28%
16,244 $428,000
Q1 2024

May 08, 2024

BUY
$30.27 - $43.79 $51,549 - $74,574
1,703 Added 9.37%
19,877 $642,000
Q4 2023

Feb 14, 2024

BUY
$31.31 - $44.19 $82,032 - $115,777
2,620 Added 16.84%
18,174 $765,000
Q3 2023

Nov 13, 2023

BUY
$18.55 - $39.96 $1,836 - $3,956
99 Added 0.64%
15,554 $597,000
Q2 2023

Aug 10, 2023

BUY
$14.2 - $23.75 $16,940 - $28,333
1,193 Added 8.36%
15,455 $293,000
Q1 2023

May 11, 2023

SELL
$15.27 - $19.72 $32,784 - $42,338
-2,147 Reduced 13.08%
14,262 $221,000
Q4 2022

Feb 02, 2023

BUY
$6.59 - $17.75 $14,405 - $38,801
2,186 Added 15.37%
16,409 $291,000
Q3 2022

Nov 04, 2022

BUY
$3.93 - $6.37 $2,589 - $4,197
659 Added 4.86%
14,223 $80,000
Q2 2022

Aug 01, 2022

SELL
$3.38 - $5.65 $20,584 - $34,408
-6,090 Reduced 30.99%
13,564 $53,000
Q1 2022

May 10, 2022

SELL
$5.06 - $8.77 $26,823 - $46,489
-5,301 Reduced 21.24%
19,654 $108,000
Q4 2021

Feb 08, 2022

SELL
$7.33 - $9.32 $34,788 - $44,232
-4,746 Reduced 15.98%
24,955 $212,000
Q3 2021

Nov 12, 2021

BUY
$7.01 - $11.37 $16,585 - $26,901
2,366 Added 8.66%
29,701 $258,000
Q2 2021

Aug 13, 2021

BUY
$9.4 - $16.85 $35,325 - $63,322
3,758 Added 15.94%
27,335 $289,000
Q1 2021

May 14, 2021

BUY
$13.08 - $49.6 $2,118 - $8,035
162 Added 0.69%
23,577 $378,000
Q4 2020

Feb 09, 2021

BUY
$36.36 - $52.71 $851,369 - $1.23 Million
23,415 New
23,415 $1.08 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.